Gapping down
In reaction to disappointing earnings/guidance:
In reaction to disappointing earnings/guidance:
- TISI -20.8%, (reports prelim Q2 results, finalizes negotiations of credit facility amendment and terminates At-the-Market equity offering program), STX -14.8%, MDR -12.6%, SANM -9.9%, CLB -6.1%, LOGI-6.1%, CRY -4.6%, EDU -4.3%, PCRX -4%, HSII -2.9%, GOOG -2.8%, APC-2.7%, MMM -2.4%, LPL -1.9%, LLY -1.5%, HXL -1.4%, CVLT -1.2%, DPZ-0.9%, WWD -0.6%
Other news:
- NVAX -19.2% (announces'positive' topline data from its Phase 2 safety and immunogenicity trial of the RSV F Vaccine in older adults, new data on RSV F vaccine, and additional findings from prior phase 2 and 3 studies of E201 and E301)
- FTI -7.7% (restates financial information due to calculations of foreign currency effects )
- INCY -3.1% (Incyte and Eli Lilly (LLY) announces the resubmission to the FDA of the NDA for baricitinib)
- WDC -2.9% (in sympathy with STX)
- MU -2.3% (in sympathy with STX)
- SLNO -1.2% (sells one of its non-strategic subsidiaries, NeoForce, Inc., which manufacturers and promotes a range of innovative pulmonary resuscitation solutions in the neonatal market, to Flexicare; terms not disclosed)
- MBRX -1.1% (files for $75 mln mixed securities shelf offering)
- SRPT -1.1% (prices 7.65 mln shares of common stock at $42.50 per share)
Analyst comments:
- UAA -2.6% (downgraded to Sell at Deutsche Bank)